← ANALYST RATINGS · TIPRANKS
Sarepta Therapeutics (SRPT): analyst forecast and price target
Analyst consensus
Hold1 Buy5 Hold3 Sell
Ratings of 9 analysts in the last 3 months · top analysts only12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $18.75, the highest $38.00, the lowest $5.00. The average is +9.6% from the last price of $17.10.
Analyst ratings 26
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Yun Zhong★★★★★★★★★★#12228 · hits 38% · avg −9.6% | Wedbush | $35.00 | Buy | +104.7% | Reiterated | 16.10.26on TipRanks 07:55 | −2.8% | ↗ |
| Unknown Analyst | Leerink Partners | $20.00 | Hold | +17.0% | Reiterated | 15.10.26on TipRanks Oct 16 07:10 | +5.4%next day −2.8% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $19.50 → $17.00−12.8% | Hold | −0.6% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $19.50 → $17.00−12.8% | Hold | −0.6% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $19.00 → $16.50−13.2% | Hold | −3.5% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $18.50 → $16.00−13.5% | Hold | −6.4% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $19.50 → $17.00−12.8% | Hold | −0.6% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $19.50 → $17.00−12.8% | Hold | −0.6% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $18.00 | Sell | +5.3% | Reiterated | 09.10.26on TipRanks 06:11 | −2.6%next day −2.2% · 5 days −2.2% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $17.00 | Hold | −0.6% | Reiterated | 08.10.26on TipRanks 08:55 | +4.5%next day −2.6% · 5 days −2.0% | ↗ |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $5.00 | Sell | −70.8% | Reiterated | 05.10.26on TipRanks 06:55 | −0.7%next day −1.6% · 5 days −0.7% | ↗ |
| Yanan Zhu★★★★★★★★★★#1136 · hits 36% · avg +15.3% | Wells Fargo | $38.00 | Buy | +122.2% | Reiterated | 02.10.26on TipRanks Oct 5 08:26 | −1.1%next day −0.7% · 5 days +0.8% | ↗ |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | $23.00 → $20.00−13.0% | Hold | +17.0% | Assigned | 30.09.26on TipRanks 07:40 | −2.0%next day −3.7% · 5 days −5.9% | ↗ |
| Lachlan Hanbury Brown★★★★★★★★★★#11394 · hits 35% · avg −5.4% | William Blair | — | Hold | — | Reiterated | 28.09.26on TipRanks 16:35 | −0.7%next day −2.0% · 5 days −9.1% | ↗ |
| Gil Blum★★★★★★★★★★#949 · hits 43% · avg +12.5% | Needham | — | Sell | — | Reiterated | 28.09.26on TipRanks 08:15 | +1.4%next day −0.7% · 5 days −8.2% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $13.00 | Sell | −24.0% | Reiterated | 27.09.26on TipRanks Sep 28 08:07 | +1.4%next day −0.7% · 5 days −8.2% | ↗ |
| Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% | Evercore ISI | $19.00 | Hold | +11.1% | Reiterated | 10.08.26on TipRanks 08:40 | +2.4%next day +6.4% · 5 days +5.9% | ↗ |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $20.00 | Hold | +17.0% | Reiterated | 07.08.26on TipRanks 04:19 | −0.6%next day +2.4% · 5 days +7.5% | ↗ |
| Kostas Biliouris★★★★★★★★★★#9060 · hits 41% · avg −0.1% | Oppenheimer | $37.00 → $35.00−5.4% | Buy | +104.7% | Reiterated | 06.08.26on TipRanks 08:31 | +5.5%next day −0.6% · 5 days +8.6% | ↗ |
| Michael Ulz★★★★★★★★★★#6183 · hits 43% · avg +0.9% | Morgan Stanley | $25.00 | Hold | +46.2% | Assigned | 06.08.26on TipRanks 07:10 | +5.5%next day −0.6% · 5 days +8.6% | ↗ |
| Biren Amin★★★★★★★★★★#1671 · hits 46% · avg +7.6% | Piper Sandler | $20.00 | Hold | +17.0% | Reiterated | 06.08.26on TipRanks 07:00 | +5.5%next day −0.6% · 5 days +8.6% | ↗ |
| Ritu Baral★★★★★★★★★★#49 · hits 58% · avg +46.9% | TD Cowen | $17.00 | Hold | −0.6% | Assigned | 06.08.26on TipRanks 06:00 | +5.5%next day −0.6% · 5 days +8.6% | ↗ |
| Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% | Cantor Fitzgerald | $21.00 | Hold | +22.8% | Reiterated | 05.08.26on TipRanks Aug 6 09:15 | −2.6%next day +5.5% · 5 days +15.0% | ↗ |
| Andy Chen★★★★★★★★★★#959 · hits 67% · avg +28.8% | Wolfe Research | $27.00 | Buy | +57.9% | Upgrade | 08.07.26on TipRanks 17:15 | +0.7%next day −8.1% · 5 days −15.9% | ↗ |
| David Hoang★★★★★★★★★★#485 · hits 67% · avg +34.8% | Deutsche Bank | $12.00 → $14.00+16.7% | Sell | −18.1% | Reiterated | 26.03.26on TipRanks 08:45 | −7.0%next day −6.2% · 5 days +5.5% | ↗ |
| Stephen Brozak★★★★★★★★★★#2946 · hits 42% · avg +10.5% | WBB Securities | $38.00 | Buy | +122.2% | Reiterated | 26.03.26on TipRanks 08:15 | −7.0%next day −6.2% · 5 days +5.5% | ↗ |
| William Pickering★★★★★★★★★★#5908 · hits 58% · avg +1.8% | Bernstein | $20.00 | Hold | +17.0% | Reiterated | 25.03.26on TipRanks Mar 26 06:30 | +34.4%next day −7.0% · 5 days −6.7% | ↗ |
| Joseph Schwartz★★★★★★★★★★#135 · hits 54% · avg +31.9% | Leerink Partners | $15.00 | Hold | −12.3% | Reiterated | 25.03.26on TipRanks 10:15 | +34.4%next day −7.0% · 5 days −6.7% | ↗ |
| Unknown Analyst | Guggenheim | $19.00 | Buy | +11.1% | Reiterated | 09.03.26on TipRanks Mar 10 13:35 | +4.7%next day +0.3% · 5 days −4.2% | ↗ |
| Brian Skorney★★★★★★★★★★#12116 · hits 37% · avg −5.6% | Robert W. Baird | $22.00 → $20.00−9.1% | Hold | +17.0% | Reiterated | 26.02.26on TipRanks 10:26 | −7.5%next day −3.5% · 5 days −5.8% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $17.00 | Hold | −0.6% | Reiterated | 25.02.26on TipRanks Feb 26 07:35 | −0.2%next day −7.5% · 5 days −14.0% | ↗ |
| Andrew Tsai★★★★★★★★★★#339 · hits 63% · avg +29.9% | Jefferies | $30.00 | Buy | +75.4% | Reiterated | 12.01.26on TipRanks 17:38 | +1.7%next day +6.7% · 5 days +0.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Sarepta Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $22.13 at a price of $18.22 (+21.5%); now: $21.53 at $17.10 (+25.9%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 3 | 2 | 2 | 2 | 2 |
| Buy | 2 | 1 | 2 | 1 | 1 | 0 |
| Hold | 13 | 9 | 8 | 6 | 9 | 9 |
| Sell | 11 | 4 | 6 | 5 | 8 | 6 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.10 (from $-0.50 to $0.78). Last quarter: $-0.05.
Sales
Next quarter’s sales estimate — $353M (from $322M to $392M). Last quarter: $401M.
Best top-analyst consensus in the sector · Healthcare
About Sarepta Therapeutics
- CEO: Michael E. Severino
- Employees: 835
- 215 First Street, Cambridge, MA, 02142, US
- www.sarepta.com
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
Data from the stock’s TipRanks forecast page, read 47 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗